{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:20:05Z","timestamp":1794640805437,"version":"4.9.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["F18-00932"],"award-info":[{"award-number":["F18-00932"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"crossref","award":["JELF-CRC 40559"],"award-info":[{"award-number":["JELF-CRC 40559"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"crossref","award":["F21-00475"],"award-info":[{"award-number":["F21-00475"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Health Canada, Substance Use and Addictions Program","award":["F22-01027"],"award-info":[{"award-number":["F22-01027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To support public health measures during the COVID-19 pandemic, oral opioid agonist treatment (OAT) take-home doses were expanded in Western countries with positive results. Injectable OAT (iOAT) take-home doses were previously not an eligible option, and were made available for the first time in several sites to align with public health measures. Building upon these temporary risk-mitigating guidelines, a clinic in Vancouver, BC continued to offer two of a possible three daily doses of take-home injectable medications to eligible clients. The present study explores the processes through which take-home iOAT doses impacted clients\u2019 quality of life and continuity of care in real-life settings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three rounds of semi-structured qualitative interviews were conducted over a period of seventeen months beginning in July 2021 with eleven participants receiving iOAT take-home doses at a community clinic in Vancouver, British Columbia. Interviews followed a topic guide that evolved iteratively in response to emerging lines of inquiry. Interviews were recorded, transcribed, and then coded using NVivo 1.6 using an interpretive description approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Participants reported that take-home doses granted them the freedom away from the clinic to have daily routines, form plans, and enjoy unstructured time. Participants appreciated the greater privacy, accessibility, and ability to engage in paid work. Furthermore, participants enjoyed greater autonomy to manage their medication and level of engagement with the clinic. These factors contributed to greater quality of life and continuity of care. Participants shared that their dose was too essential to divert and that they felt safe transporting and administering their medication off-site. In the future, all participants would like more accessible treatment such as access longer take-home prescriptions (e.g., one week), the ability to pick-up at different and convenient locations (e.g., community pharmacies), and a medication delivery service.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Reducing the number of daily onsite injections from two or three to only one revealed the diversity of rich and nuanced needs that added flexibility and accessibility in iOAT can meet. Actions such as licencing diverse opioid medications\/formulations, medication pick-up at community pharmacies, and a community of practice that supports clinical decisions are necessary to increase take-home iOAT accessibility.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-023-09558-6","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T13:02:52Z","timestamp":1685106172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clients\u2019 experiences on North America\u2019s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study"],"prefix":"10.1186","volume":"23","author":[{"given":"Eugenia","family":"Oviedo-Joekes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Dobischok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"McDermid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Klakowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"LaJeunesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"9558_CR1","doi-asserted-by":"crossref","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the global burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987\u20131012.","DOI":"10.1016\/S2215-0366(18)30337-7"},{"key":"9558_CR2","doi-asserted-by":"crossref","unstructured":"Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:1\u20137.","DOI":"10.1016\/j.drugalcdep.2020.108350"},{"key":"9558_CR3","unstructured":"Government of British Columbia. Provincial health officer declares public health emergency. 2016."},{"key":"9558_CR4","doi-asserted-by":"crossref","unstructured":"Haffajee RL, Frank RG. Making the opioid public health emergency effective. JAMA Psychiatry. 2018;75:767\u20138.","DOI":"10.1001\/jamapsychiatry.2018.0611"},{"key":"9558_CR5","unstructured":"Health Canada. Safer Supply. 2022 [cited 2023 Jan 31]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/responding-canada-opioid-crisis\/safer-supply.html#a1."},{"key":"9558_CR6","doi-asserted-by":"crossref","unstructured":"Beck T, Haasen C, Verthein U, Walcher S, Schuler C, Backmund M, et al. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction. 2014;109(4):617\u201326.","DOI":"10.1111\/add.12440"},{"key":"9558_CR7","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014(2):CD002209.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"9558_CR8","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009(3):CD002209.","DOI":"10.1002\/14651858.CD002209.pub2"},{"key":"9558_CR9","doi-asserted-by":"crossref","unstructured":"Krawczyk N, Mojtabai R, Stuart EA, Fingerhood M, Agus D, Lyons BC, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9):1683\u201394.","DOI":"10.1111\/add.14991"},{"key":"9558_CR10","doi-asserted-by":"crossref","unstructured":"Santo T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of Opioid Agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and Meta-analysis. JAMA Psychiatry. 2021;78(9):979\u201393.","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"key":"9558_CR11","doi-asserted-by":"crossref","unstructured":"Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019;74:257\u201365.","DOI":"10.1016\/j.drugpo.2019.01.020"},{"key":"9558_CR12","doi-asserted-by":"crossref","unstructured":"Kourounis G, Richards BDW, Kyprianou E, Symeonidou E, Malliori MM, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161;1\u20138.","DOI":"10.1016\/j.drugalcdep.2015.12.021"},{"key":"9558_CR13","doi-asserted-by":"crossref","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. \u201cIt\u2019s like \u2018liquid handcuffs\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives. Harm Reduct J. 2021;18(1):88.","DOI":"10.1186\/s12954-021-00535-y"},{"key":"9558_CR14","unstructured":"CRISM National Guideline Review Committee. National Guideline for the Clinical Management of Opioid Use Disorder. 2018. Available from: http:\/\/www.cihr-irsc.gc.ca\/e\/44597.html."},{"key":"9558_CR15","unstructured":"British Columbia Centre on Substance Use, BC Ministry of Health. A Guideline for the Clinical Management of Opioid Use Disorder. 2017. Available from: http:\/\/www.bccsu.ca\/care-guidance-publications\/."},{"key":"9558_CR16","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment Improvement Protocol 63: Medications for Opioid Use Disorder. 2021. Available from: https:\/\/www.surveymonkey.com\/r\/KAPPFS."},{"key":"9558_CR17","doi-asserted-by":"crossref","unstructured":"Meteliuk A, Galvez de Leon SJ, Madden LM, Pykalo I, Fomenko T, Filippovych M, et al. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. J Subst Abuse Treat. 2021;121:108164.","DOI":"10.1016\/j.jsat.2020.108164"},{"key":"9558_CR18","doi-asserted-by":"crossref","unstructured":"Meyer M, Strasser J, K\u00f6ck P, Walter M, Vogel M, D\u00fcrsteler KM. Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic\u2013Is an update of legal restrictions warranted? Int J Drug Policy. 2022;101:103548.","DOI":"10.1016\/j.drugpo.2021.103548"},{"key":"9558_CR19","doi-asserted-by":"crossref","unstructured":"Kitchen SA, Campbell TJ, Men S, Bozinoff N, Tadrous M, Antoniou T, et al. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: a population-based time-series analysis. Int J Drug Policy. 2022;103:103644.","DOI":"10.1016\/j.drugpo.2022.103644"},{"issue":"6","key":"9558_CR20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","volume":"47","author":"O Amram","year":"2021","unstructured":"Amram O, Amiri S, Panwala V, Lutz R, Joudrey PJ, Socias E. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. Am J Drug Alcohol Abuse. 2021;47(6):722\u20139.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"9558_CR21","doi-asserted-by":"crossref","unstructured":"Russell C, Lange S, Kouyoumdjian F, Butler A, Ali F. Opioid agonist treatment take-home doses (\u2018carries\u2019): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA? Harm Reduct J. 2022;19(1):89.","DOI":"10.1186\/s12954-022-00671-z"},{"key":"9558_CR22","doi-asserted-by":"crossref","unstructured":"Adams A, Blawatt S, Macdonald MS, Finnick R, Lajeunesse J, Harrison S, et al. Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review. Int J Drug Policy. 2023;117:104058.","DOI":"10.1016\/j.drugpo.2023.104058"},{"key":"9558_CR23","doi-asserted-by":"crossref","unstructured":"Madden EF, Christian BT, Lagisetty PA, Ray BR, Sulzer SH. Treatment provider perceptions of take-home methadone regulation before and during COVID-19. Drug Alcohol Depend. 2021;228:109100.","DOI":"10.1016\/j.drugalcdep.2021.109100"},{"key":"9558_CR24","doi-asserted-by":"crossref","unstructured":"Amiri S, Lutz R, Soc\u00edas E, McDonell MG, Roll JM, Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst Abuse Treat. 2018;93:26\u201330.","DOI":"10.1016\/j.jsat.2018.07.006"},{"key":"9558_CR25","doi-asserted-by":"crossref","unstructured":"Lintzeris N, Deacon RM, Hayes V, Cowan T, Mills L, Parvaresh L, et al. Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia. Drug Alcohol Rev. 2022;41(5):1009\u201319.","DOI":"10.1111\/dar.13382"},{"key":"9558_CR26","doi-asserted-by":"crossref","unstructured":"Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, et al. Association between increased dispensing of Opioid Agonist Therapy take-home doses and opioid overdose and treatment interruption and discontinuation. JAMA. 2022;327(9):846\u201355.","DOI":"10.1001\/jama.2022.1271"},{"key":"9558_CR27","doi-asserted-by":"crossref","unstructured":"Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2011.","DOI":"10.1002\/14651858.CD003410.pub4"},{"key":"9558_CR28","doi-asserted-by":"crossref","unstructured":"Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207(1):5\u201314.","DOI":"10.1192\/bjp.bp.114.149195"},{"key":"9558_CR29","doi-asserted-by":"crossref","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence. JAMA Psychiatry. 2016;73(5):447\u201355.","DOI":"10.1001\/jamapsychiatry.2016.0109"},{"key":"9558_CR30","doi-asserted-by":"crossref","unstructured":"Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ. 2012;184(6):E317\u201328.","DOI":"10.1503\/cmaj.110669"},{"key":"9558_CR31","doi-asserted-by":"crossref","unstructured":"Bansback N, Guh D, Oviedo-Joekes E, Brissette S, Harrison S, Janmohamed A, et al. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction. 2018;113(7):1264\u201373.","DOI":"10.1111\/add.14171"},{"key":"9558_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-2125.2012.04317.x","volume":"75","author":"AM Drewes","year":"2013","unstructured":"Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol. 2013;75:60\u201378.","journal-title":"Br J Clin Pharmacol"},{"key":"9558_CR33","unstructured":"Strang J, Groshkova T, Metrebian N. New heroin-assisted treatment - recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond. EMCDDA Insights. 2012."},{"key":"9558_CR34","doi-asserted-by":"crossref","unstructured":"Strang L, Taylor J. Heroin-Assisted Treatment and Supervised Drug Consumption Sites: Experience from Four Countries. 2018. Available from: www.rand.org\/giving\/contribute.","DOI":"10.7249\/WR1262"},{"key":"9558_CR35","doi-asserted-by":"crossref","unstructured":"Marchand K, Palis H, Guh D, Lock K, MacDonald S, Brissette S, et al. A multi-methods and longitudinal study of patients\u2019 perceptions in injectable opioid agonist treatment: implications for advancing patient-centered methodologies in substance use research. J Subst Abuse Treat. 2021;132:108512.","DOI":"10.1016\/j.jsat.2021.108512"},{"key":"9558_CR36","unstructured":"Canadian Research Initiative in Substance Misuse (CRISM). National Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline. 2019. Available from: https:\/\/crism.ca\/projects\/ioat-guideline\/."},{"key":"9558_CR37","doi-asserted-by":"crossref","unstructured":"Fairbairn N, Ross J, Trew M, Meador K, Turnbull J, MacDonald S, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ. 2019;191(38):E1049\u201356.","DOI":"10.1503\/cmaj.190344"},{"key":"9558_CR38","doi-asserted-by":"crossref","unstructured":"Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):7.","DOI":"10.1186\/s13011-020-0253-y"},{"key":"9558_CR39","doi-asserted-by":"crossref","unstructured":"Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, et al. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder. Drug Alcohol Depend. 2017;176:55\u201362.","DOI":"10.1016\/j.drugalcdep.2017.02.021"},{"key":"9558_CR40","doi-asserted-by":"crossref","unstructured":"Dobischok S, Metcalfe RK, Matzinger EA, Lock K, Harrison S, MacDonald S, et al. Feasibility of testing client preferences for accessing Injectable opioid agonist treatment (iOAT): a pilot study. Patient Prefer Adherence. 2022;16:3405\u201313.","DOI":"10.2147\/PPA.S391532"},{"key":"9558_CR41","volume-title":"How iOAT care could be improved? Providers perspectives on clients\u2019 needs","author":"T Magel","year":"2023","unstructured":"Magel T, Matzinger E, Blawatt S, Harrison S, MacDonald S, Amara S, et al. How iOAT care could be improved? Providers perspectives on clients\u2019 needs. Drugs: Education, Prevention and Policy. 2023:1\u201312."},{"key":"9558_CR42","doi-asserted-by":"crossref","unstructured":"Martins ML, Wilthagen EA, Oviedo-Joekes E, Beijnen JH, de Grave N, Uchtenhagen A, et al. The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. Drug Alcohol Depend. 2021;227:108984.","DOI":"10.1016\/j.drugalcdep.2021.108984"},{"key":"9558_CR43","doi-asserted-by":"crossref","unstructured":"Larance B, Degenhardt L, Lintzeris N, Winstock A, Mattick R. Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug Alcohol Rev. 2011;30(3):236\u201345.","DOI":"10.1111\/j.1465-3362.2010.00283.x"},{"key":"9558_CR44","doi-asserted-by":"crossref","unstructured":"Strang J, Gossop M. Heroin prescribing in the British system: historical review. Eur Addict Res. 1996;2(4):185\u201393.","DOI":"10.1159\/000259131"},{"key":"9558_CR45","doi-asserted-by":"crossref","unstructured":"Dennis F. Advocating for diamorphine: cosmopolitical care and collective action in the ruins of the \u2018old british system.\u2019 Crit Public Health. 2021;31(2):144\u201355.","DOI":"10.1080\/09581596.2020.1772463"},{"key":"9558_CR46","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug misuse and dependence: UK guidelines on clinical management. 2017."},{"key":"9558_CR47","unstructured":"The Federal Council of the Swiss Government. Coronavirus: The Federal Council adapts the criteria for the delivery of medical heroin. Berne; 2020 [cited 2023 Jan 17]. Available from: https:\/\/www.admin.ch\/gov\/fr\/accueil\/documentation\/communiques.msg-id-80511.html."},{"key":"9558_CR48","doi-asserted-by":"crossref","unstructured":"Oviedo-Joekes E, MacDonald S, Boissonneault C, Harper K. Take home injectable opioids for opioid use disorder during and after the COVID-19 pandemic is in urgent need: a case study. Subst Abuse Treat Prev Policy. 2021;16(1):22.","DOI":"10.1186\/s13011-021-00358-x"},{"key":"9558_CR49","doi-asserted-by":"crossref","unstructured":"Oviedo-Joekes E, Palis H, Guh D, Marsh DC, MacDonald S, Harrison S, et al. Adverse events during treatment induction with Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder. J Addict Med. 2019;13(5):354\u201361.","DOI":"10.1097\/ADM.0000000000000505"},{"key":"9558_CR50","unstructured":"Woo A. Vancouver clinic revokes 11 patients\u2019 access to take-home heroin doses. In: The Globe and Mail. 2021. Available from: https:\/\/www.theglobeandmail.com\/canada\/article-vancouver-clinic-revokes-11-patients-access-to-take-home-heroin-doses\/. Accessed May 2023."},{"key":"9558_CR51","doi-asserted-by":"crossref","unstructured":"Thorne S, Reimer Kirkham S, O\u2019flynn-Magee K. The analytic challenge in interpretive description. Int J Qual Methods. 2004;3. Available from: http:\/\/www.ualberta.ca\/~iiqm\/backissues\/3_1\/pdf\/thorneetal.pdf.","DOI":"10.1177\/160940690400300101"},{"key":"9558_CR52","volume-title":"Interpretive description: qualitative research for Applied Practice","author":"S Thorne","year":"2016","unstructured":"Thorne S. Interpretive description in process. Interpretive description: qualitative research for Applied Practice. 2nd ed. New York: Routledge; 2016.","edition":"2"},{"key":"9558_CR53","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qualitative research in Sport, Exercise and Health. 2019;11:589\u201397.","DOI":"10.1080\/2159676X.2019.1628806"},{"key":"9558_CR54","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/09638288.2019.1602850","volume":"42","author":"P Solomon","year":"2020","unstructured":"Solomon P, Nixon S, Bond V, Cameron C, Gervais N. Two approaches to longitudinal qualitative analyses in rehabilitation and disability research. Disabil Rehabil. 2020;42(24):3566\u201372.","journal-title":"Disabil Rehabil"},{"key":"9558_CR55","doi-asserted-by":"crossref","unstructured":"Browne C. Critical Social Theory. SAGE Publications Ltd; 2017.","DOI":"10.4135\/9781473911819"},{"key":"9558_CR56","volume-title":"Discipline and Punish: the birth of the prison","author":"M Foucault","year":"1977","unstructured":"Foucault M. Discipline and Punish: The Birth of the Prison. In: Sheridan A, editor. New York: Vintage Books; 1977."},{"key":"9558_CR57","doi-asserted-by":"crossref","unstructured":"Corbin JM, Strauss A. Grounded theory research: procedures, canons, and evaluative criteria. Qual Sociol. 1990;13(1):3\u201321.","DOI":"10.1007\/BF00988593"},{"key":"9558_CR58","unstructured":"MacDonald S, Oviedo-Joekes E. Injectable opioid agonist therapy. In: Selby P, Rieb L, Lam V, Zhang M, Bertram J, editors. Opioid Agonist Therapy: A Prescriber\u2019s Guide to Treatment. 3rd ed. Centre for Addition and Mental Health; 2022;13:99\u2013108."},{"issue":"1","key":"9558_CR59","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/08897077.2022.2060438","volume":"43","author":"LW Suen","year":"2022","unstructured":"Suen LW, Castellanos S, Joshi N, Satterwhite S, Knight KR. The idea is to help people achieve greater success and liberty\u201d: a qualitative study of expanded methadone take-home access in opioid use disorder treatment. Subst Abus. 2022;43(1):1143\u201350.","journal-title":"Subst Abus"},{"key":"9558_CR60","doi-asserted-by":"crossref","unstructured":"Hoffman KA, Foot C, Levander XA, Cook R, Terashima JP, McIlveen JW, et al. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: a mixed methods analysis. J Subst Abuse Treat. 2022;141:108801.","DOI":"10.1016\/j.jsat.2022.108801"},{"key":"9558_CR61","doi-asserted-by":"crossref","unstructured":"Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Substance Abuse: Treatment, Prevention, and Policy. 2019;14(1):37.","DOI":"10.1186\/s13011-019-0227-0"},{"key":"9558_CR62","doi-asserted-by":"crossref","unstructured":"Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000;51(7);1087\u2013110.","DOI":"10.1016\/S0277-9536(00)00098-8"},{"key":"9558_CR63","doi-asserted-by":"crossref","unstructured":"Scholl I, Zill JM, H\u00e4rter M, Dirmaier J. An integrative model of patient-centeredness-A systematic review and concept analysis. PLoS ONE. 2014;9(9):e107828.","DOI":"10.1371\/journal.pone.0107828"},{"key":"9558_CR64","doi-asserted-by":"crossref","unstructured":"Park S, Grogan CM, Mosley JE, Humphreys K, Pollack HA, Friedmann PD. Correlates of patient-centered care practices at U.S. Substance use disorder clinics. Psychiatric Serv. 2020;71(1):35\u201342.","DOI":"10.1176\/appi.ps.201900121"},{"key":"9558_CR65","doi-asserted-by":"crossref","unstructured":"Jaffe JH, O\u2019Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2 Suppl):S3\u201311.","DOI":"10.1016\/S0376-8716(03)00055-3"},{"key":"9558_CR66","doi-asserted-by":"crossref","unstructured":"Wright N, D\u2019Agnone O, Krajci P, Littlewood R, Alho H, Reimer J, et al. Addressing misuse and diversion of opioid substitution medication: Guidance based on systematic evidence review and real-world experience. J Public Health (United Kingdom). 2016;38(3):e368\u201374.","DOI":"10.1093\/pubmed\/fdv150"},{"key":"9558_CR67","doi-asserted-by":"crossref","unstructured":"Duthie K, Mathison E, Eyford H, Monty Ghosh S, Dossetor J. Prescribing safe supply: ethical considerations for clinicians. J Med Ethics. 2022;0:1\u20136.","DOI":"10.1136\/jme-2021-108087"},{"key":"9558_CR68","doi-asserted-by":"crossref","unstructured":"Bromley LA. Problems with hydromorphone prescribing as a response to the opioid crisis. CMAJ. 2020;192:E219\u201320.","DOI":"10.1503\/cmaj.74065"},{"key":"9558_CR69","doi-asserted-by":"crossref","unstructured":"Reimer J, Wright N, Somaini L, Roncero C, Maremmani I, Mckeganey N, et al. The impact of misuse and diversion of opioid substitution treatment medicines: evidence review and expert consensus. Eur Addict Res 2016;22(2):99\u2013106.","DOI":"10.1159\/000438988"},{"key":"9558_CR70","unstructured":"British Columbia Centre on Substance Use. COVID-19: information for opioid agonist treatment prescribers and pharmacists. 2020."},{"key":"9558_CR71","unstructured":"Safer Supply Community of Practice. Reframing Diversion for Health Care Providers. 2022."},{"key":"9558_CR72","doi-asserted-by":"crossref","unstructured":"Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abuse Treat. 2021;123:108276.","DOI":"10.1016\/j.jsat.2021.108276"},{"key":"9558_CR73","doi-asserted-by":"crossref","unstructured":"Bardwell G, Small W, Lavalley J, McNeil R, Kerr T. \u201cPeople need them or else they\u2019re going to take fentanyl and die\u201d: a qualitative study examining the \u2018problem\u2019 of prescription opioid diversion during an overdose epidemic. Soc Sci Med. 2021;279:113986.","DOI":"10.1016\/j.socscimed.2021.113986"},{"key":"9558_CR74","doi-asserted-by":"crossref","unstructured":"Reddon H, Ho J, DeBeck K, Milloy MJ, Liu Y, Dong H, et al. Increasing diversion of methadone in Vancouver, Canada, 2005\u20132015. J Subst Abuse Treat. 2018:85:10\u20136.","DOI":"10.1016\/j.jsat.2017.11.010"},{"issue":"3","key":"9558_CR75","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1046\/j.1360-0443.2000.95339310.x","volume":"95","author":"J Fountain","year":"2000","unstructured":"Fountain J, Strang J, Gossop M, Farrell M, Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction. 2000;95(3):393\u2013406.","journal-title":"Addiction"},{"key":"9558_CR76","doi-asserted-by":"crossref","unstructured":"Bardwell G, Ivsins A, Soc\u00edas ME, Kerr T. Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: a qualitative study in Vancouver, Canada. J Subst Abuse Treat. 2021;130:108418.","DOI":"10.1016\/j.jsat.2021.108418"},{"key":"9558_CR77","doi-asserted-by":"crossref","unstructured":"Roux P, Rojas Castro D, Ndiaye K, Briand Madrid L, Laporte V, Mora M, et al. Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France. Subst Abuse Treat Prev Policy. 2017;12(1):46.","DOI":"10.1186\/s13011-017-0131-4"},{"key":"9558_CR78","doi-asserted-by":"crossref","unstructured":"Mezaache S, Carrieri P, Briand-Madrid L, Laporte V, Morel A, Rojas Castro D, et al. Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France. Harm Reduct J. 2021;18(1):11.","DOI":"10.1186\/s12954-021-00460-0"},{"key":"9558_CR79","doi-asserted-by":"crossref","unstructured":"McLean K, Kavanaugh PR. \u201cThey\u2019re making it so hard for people to get help:\u201d motivations for non-prescribed buprenorphine use in a time of treatment expansion. Int J Drug Policy. 2019:71:118\u201324.","DOI":"10.1016\/j.drugpo.2019.06.019"},{"key":"9558_CR80","doi-asserted-by":"crossref","unstructured":"Peters JL, Durand WM, Monteiro KA, Dumenco L, George P. Opioid overdose hospitalizations among medicare-disability beneficiaries. J Am Board Family Med. 2018;31(6):881\u201396.","DOI":"10.3122\/jabfm.2018.06.180152"},{"key":"9558_CR81","doi-asserted-by":"crossref","unstructured":"Glazier RE, Kling RN. Recent trends in substance abuse among persons with disabilities compared to that of persons without disabilities. Disabil Health J. 2013;6(2):107\u201315.","DOI":"10.1016\/j.dhjo.2013.01.007"},{"key":"9558_CR82","doi-asserted-by":"crossref","unstructured":"Conway A, Treloar C, Crawford S, Degenhardt L, Dore GJ, Farrell M, et al. \u201cYou\u2019ll come in and dose even in a global pandemic\u201d: a qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic. Int J Drug Policy. 2023;114:103998.","DOI":"10.1016\/j.drugpo.2023.103998"},{"key":"9558_CR83","doi-asserted-by":"crossref","unstructured":"Corace K, Suschinsky K, Wyman J, Leece P, Cragg S, Konefal S, et al. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: patients\u2019 and prescribers\u2019 experiences with changes in unsupervised dosing. Int J Drug Policy. 2022;102:103573.","DOI":"10.1016\/j.drugpo.2021.103573"},{"key":"9558_CR84","doi-asserted-by":"crossref","unstructured":"Suen LW, Castellanos S, Joshi N, Satterwhite S, Knight KR. \u201cThe idea is to help people achieve greater success and liberty\u201d: A qualitative study of expanded methadone take-home access in opioid use disorder treatment. Subst Abus. 2022;43(1):1143\u201350.","DOI":"10.1080\/08897077.2022.2060438"},{"key":"9558_CR85","doi-asserted-by":"crossref","unstructured":"Palis H, Marchand K, Guh D, Brissette S, Lock K, MacDonald S, et al. Men\u2019s and women\u2019s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder. Subst Abuse Treat Prev Policy. 2017;12(1):25.","DOI":"10.1186\/s13011-017-0110-9"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-09558-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T13:06:43Z","timestamp":1685106403000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-09558-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["9558"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-09558-6","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All research activities were approved by the Providence Health Care Research Ethics Board (harmonized board of record) and Fraser Health Authority (harmonized partner board) [H19-00217]. All participants provided informed consent and were monetarily compensated for their time. All methods were carried out in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"553"}}